key: cord-0772014-wjp66whk
authors: Beduneau, Gaëtan; Boyer, Déborah; Guitard, Pierre-Gildas; Gouin, Philippe; Carpentier, Dorothée; Grangé, Steven; Veber, Benoit; Girault, Christophe; Tamion, Fabienne
title: Covid-19 severe hypoxemic pneumonia: a clinical experience using high-flow nasal oxygen therapy as first-line management
date: 2021-06-04
journal: Respir Med Res
DOI: 10.1016/j.resmer.2021.100834
sha: b632f8252df3354d2a24a698f360cce30baed29a
doc_id: 772014
cord_uid: wjp66whk

Purpose: To report a French experience in patients admitted to Intensive Care Unit (ICU) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requiring high fractional concentration of inspired oxygen supported by high flow nasal cannula (HFNC) as first-line therapy. Methods: Retrospective cohort study conducted in two ICUs of a French university hospital. All consecutive patients admitted during 28-days after the first admission for SARS-CoV-2 pneumonia were screened. Demographic, clinical, respiratory support, specific therapeutics, ICU length-of-stay and survival data were collected. Results: Data of 43 patients were analyzed: mainly men (72%), median age 61 (51-69) years, median body mass index of 28 (25-31) kg/m2, median simplified acute physiology score (SAPS II) of 29 (22-37) and median PaO2/fraction of inspired oxygen (FiO2) (P/F) ratio of 146 (100-189) mmHg. HFNC was initiated at ICU admission in 76% of patients. Median flow was 50 (45-50) L/min and median FiO2 was 0.6 (0.5-0.8). 79% of patients presented at least one comorbidity, mainly hypertension (58%). At day (D) 28, 32% of patients required invasive mechanical ventilation, 3 patients died in ICU. Risk factors for intubation were diabetes (10% vs 43%, p=0.04) and extensive lesions on chest computed tomography (CT) (p=0.023). Patients with more than 25% of lesions on chest CT were more frequently intubated during ICU stay (p=0.012). At ICU admission (D1), patients with higher SAPS II and Sequential Organ Failure Assessment (SOFA) scores (respectively 39 (28-50) vs 27 (22-31), p=0.0031 and 5 (2-8) vs 2 (2-2.2), p=0.0019), and a lower P/F ratio (98 (63-109) vs 178 (126-206), p=0.0005) were more frequently intubated.Among non-intubated patients, the median lowest P/F was 131 (85-180) mmHg. Four caregivers had to stop working following coronavirus 2 contamination, but did not require hospitalization. Conclusion: Our clinical experience supports the use of HFNC as first line-therapy in patients with SARS-COV-2 pneumonia for whom face mask oxygen does not provide adequate respiratory support.

In December 2019, the first case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was diagnosed in China. SARS-CoV-2 is responsible for a rapidly spreading illness (1) known as Coronavirus Disease 2019 . Up to one third of patients hospitalized for SARS-CoV-2 infection require Intensive Care Unit (ICU) management. Severe COVID-19 may progress to acute hypoxemic respiratory failure requiring high fractional concentration of inspired oxygen (FiO2) and different ventilation strategies.

High-flow nasal cannula (HFNC) is a non-invasive technique of respiratory support used in critically ill patients with acute hypoxemic respiratory failure (2) . However, HFNC may cause aerosol dispersion of infectious particles and therefore was not initially recommended as first-line respiratory therapy for SARS-CoV-2 infection by some experts (3) .

In France, invasive ventilation was widely used from the start of the COVID-19 outbreak in the regions first affected, especially in the east of France, with a rapid saturation of ICU beds (4) . In our center in the north-west of France, we have used HFNC oxygen therapy for several decades to manage ICU patients with hypoxemic pneumonia (5) . We used this same technique of respiratory support to manage ICU patients with SARS-CoV-2 pneumonia. We implemented protective measures for all caregivers according to WHO and French recommendations (6), (7) . Later publications reported the use of HFNC oxygen therapy, either in connection with the use of non-invasive methods of oxygen therapy (8), (9) , or in connection with physio-pathological considerations of these COVID-related pneumonias (10), (11) .

The aim of this retrospective study was to report a French experience in patients admitted to ICU for SARS-CoV-2 pneumonia requiring high fractional concentration of inspired oxygen, supported by HFNC oxygen as systematic first-line respiratory therapy.

Design:

This retrospective observational cohort study was conducted in two ICUs (one medical ICU of 27 beds, and one surgical ICU of 23 beds) of Rouen University Hospital, Normandy, France.

All consecutive patients admitted to these two ICUs during the 28 days following the first SARS-CoV-2 pneumonia admission on March 13th, 2020 were screened. The diagnosis of SARS-CoV-2 pneumonia was based on clinical characteristics, chest imaging and real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay.

Other patients with a diagnosis of SARS-CoV-2 pneumonia and hospitalized in a COVID ICU created de novo were excluded because of difficulty of data collection and possible influence on treatment specifically related to an unusual environment.

The study protocol was approved by the local ethics committee and the institutional review board (approval number E2020-31). Patients (or surrogates) were informed by letter of the study based on anonymous data from their medical file.

Patients' demographic characteristics: age, sex, body mass index (BMI), severity scores (Simplified Acute Physiology Score (SAPS) II score (12) , Sequential

Organ Failure Assessment (SOFA) (13) and comorbidities were recorded at baseline for all patients. Dates of first symptoms, hospital and ICU admissions J o u r n a l P r e -p r o o f 6 and computed tomography (CT) results when performed within 24 hours of admission to ICU were reported. Daily respiratory support devices (oxygen mask, HFNC, non-invasive ventilation or invasive ventilation), fraction of inspired oxygen (FiO2) (14) and oxygen flow in case of high-flow oxygen therapy, respiratory rate, arterial blood gas, specific therapies for COVID 19, and adjuvant therapies for acute respiratory distress syndrome (ARDS) such as use of continuous neuromuscular blockers, nitric oxide or prone position until day 28 (D28) were also recorded. Data regarding hemodynamic failure, defined as the use of norepinephrine, and kidney failure, defined as a score ≥3 on "Kidney Disease: Improving Global Outcomes" (KDIGO) were recorded. The following outcomes were evaluated: dates of weaning from invasive mechanical ventilation or from HFNC, dates of ICU and hospital discharge, ICU mortality and D28 mortality.

Characteristics of patients are described as frequencies and percentages for categorical variables and medians and interquartile ranges (IQR) for continuous variables. Categorical variables were compared using chi-square or Fisher's exact test, and continuous variables were compared using Student's t-test or Wilcoxon's rank-sum test. We retained a p value of 0.05.

Study population:

From March 13th to April 11th, 2020, 98 patients consecutively admitted to two ICUs for SARS-CoV-2 pneumonia with acute respiratory failure (ARF) were eligible for inclusion. Among them, 45 patients transferred from another region of France were not considered because of a lack of information on the initial 7 severity of the disease. A majority of them had been initially intubated notably to secure medical transport. Fifty-three patients were eligible for enrollment and, finally, after exclusion of 10 patients for initial decision of palliative care or flow of standard oxygen below 6 L/min, 43 patients were analyzed (Fig. 1) .

The decision to intubate was based on the analysis of the clinician in charge of the patient regarding respiratory exhaustion, hemodynamic or neurological failure, but not on the sole criterion of oxygenation.

Patient's general characteristics ( Table 1 ):

The characteristics of the 43 patients are presented in table 1. A majority were men (72%), with a median age of 61 (51.5 to 69.5) years, a median BMI of 28 (25.2 to 31) kg/m 2 . Patients were admitted to ICU in a median time of 9 (6 to 11) days after the onset of symptoms; 79% presented at least one comorbidity, mainly hypertension (58%).

Patients' characteristics at ICU admission and during ICU stay ( Table 2) :

The median SAPS II was 29 (22.5 to 37) and the median PaO 2 /FiO 2 (P/F) ratio was 146 (100-189) mmHg. HFNC was initiated at ICU admission in the majority of patients (33, 76%), with a median flow of 50 (45 to 50) L/min and a median FiO2 of 0.6 (0.5 to 0.8).

At D28, 32% of patients required invasive mechanical ventilation, 30% had hemodynamic failure and 16% had renal failure. We did not use non-invasive ventilation or awake prone positioning in these patients.

Patients' outcomes ( In patients with invasive ventilation, we observed more hemodynamic and kidney failure (respectively, 13 vs 0, p=0.002 and 5 vs 2, p=0.026), a longer median length of ICU stay (28 (19 to 28) vs 6 (3 to 8) days, p=0.00001) and more mortality (3 vs 0, p=0.013).

Among not-intubated patients, the lowest P/F was 131 mmHg.

During the study period, four staff members were contaminated with Covid-19 leading to work disruption, but they did not require hospitalization. To our knowledge, they were not contaminated in the ICU.

Outcomes at three months are presented in supplementary table 1.

Based on the results of our clinical experience, HFNC could represent a safe and effective strategy of first-line oxygenation for patients with severe hypoxemic pneumonia due to SARS-COV-2. More than two thirds of our patients were not intubated, despite a PaO2/FiO2 ratio below 200 mmHg at admission and, a lowest PaO2/FiO2 ratio of 131 mmHg during ICU hospitalization, for nonintubated patients. Related to this strategy, we observed a mortality rate of only 7% at day 28 despite a severe SAPS II score of 29 at admission.

Intubating hypoxemic patients wisely remains a major challenge. The value of using HFNC is based on recent research, especially from Frat and colleagues (2) . A recent systematic review showed that HFNC, in patients with acute hypoxemic respiratory failure, was associated with similar outcomes compared to noninvasive ventilation or conventional oxygen therapy, regarding mortality and ICU length of stay (15) . In our study the decision to intubate was based on the analysis of the clinician in charge of the patient, in particular in view of the presence of signs of respiratory distress or associated visceral failure. We did not use the "ROX index", as suggested in a letter published after our study period (16) . The use of HFNC in patients with severe acute respiratory viral infection was previously described in a cohort of ICU patients hospitalized with H1N1 Influenza A (19) . HFNC appears to be an effective modality for the early respiratory support of adults with severe acute respiratory viral infection. A recent small study from China showed that among 17 patients with hypoxemic pneumonia due to SARS-COV-2 pneumonia treated with HFNC, 7 (41%) experienced treatment failure, and among patients with PaO 2 /FiO 2 < 200 mmHg, failure rates reached 63% (20) . Other authors highlighted an association between excess of mortality and a SAPS II score threshold of 17 (21) . It is interesting to note that our population was more severe in terms of SAPS II and hypoxemia than those recently analyzed (20) , (21) . Moreover, an Italian observational study reported the success of HFNC in patients with a low PaO 2 /FiO 2 ratio of 126 mmHg (22) . We hypothesize that our early use of HFNC, In addition, the good outcome of our patients treated with HFNC was associated with a decreased risk of subsequent intubation. This point is crucial in the current pandemic as medical resources worldwide are limited, particularly ICU capacity and specific drug supplies in the first stages of any invasive mechanical ventilation, namely powerful sedatives and neuroblockers. After our data collection, Demoule et al (9) published a retrospective study of 379 patients among whom 146 (39%) received HFNC within the first 24 hours following ICU admission. A propensity score matched analysis was performed: results suggest that HFNC significantly reduces intubation and subsequent invasive mechanical ventilation, without effect on mortality. In our study, D28 ICU mortality was found notably low (7%). The specificities of our population (both early and systematic use of first-line HFNC) do not allow a direct comparison between this result and that of the recent French multicenter "Covid ICU" study (25) as well as that of Contou et al. (26) . Our interesting result, however, should encourage ICU physicians to confirm the benefit of an early and systematic use of first-line HFNC in this setting based on a prospective multicenter study.

Our study presents several limitations. First it is a retrospective study, including a small number of patients. Due to this small number, we did not search for predictive factors by multivariate analysis. However, the population was relatively homogeneous exhibiting a similar respiratory pathology due to Covid-19. Also, we only included patients from the local area, who were consecutively admitted to our two ICUs during a one-month period. These patients were all deemed eligible to receive specific care in a skilled environment for the application of this technique of ventilatory support. Our results may not be generalizable, therefore, to other centers or in other conditions. Nevertheless, the early and systematic use of this technique allowed us to progressively increase the number of ICU beds when needed, thus making it possible to maintain our high level of usual care, and vice versa. Moreover, we did not compare our respiratory strategy based on HFNC as first choice with the common strategy used in other French centers, based on systematic early intubation despite a relative standard level of oxygen. Such a comparative analysis has to be carried out.

This French clinical experience supports the use of HFNC as first line management in patients with acute respiratory failure due to SARS-COV-2 pneumonia for whom standard face mask oxygen does not provide adequate respiratory support. The use of HFNC may reduce the overall rate of intubation in ICU and improve patient outcomes without any major risk of contamination among caregivers, providing that adequate protection measures are strictly observed. The COVID-19 pandemic still requires further comprehensive riskbenefit analysis to consider HFNC as an alternative technique of respiratory support in patients presenting with acute respiratory failure. 

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure

Recommandations d'experts portant sur la prise en charge en réanimation des patients en période d'épidémie à SARS-CoV2

The outbreak of COVID-19 in Mulhouse: Hospital crisis management and deployment of military hospital during the outbreak of COVID-19 in Mulhouse

High-flow nasal cannula therapy: clinical practice in intensive care units

World health organisation. Rational use of personal protective equipment for coronavirus disease 2019 (COVID-19)

Société française d'hygiène hospitalière SF2H. Avis relatif aux indications du port des masques chirurgicaux et des appareils de protection respiratoire de type FFP2 pour les professionnels de santé

Use of non-invasive ventilation for patients with COVID-19: a cause for concern?

High-Flow Nasal Cannula in Critically III Patients with Severe COVID-19

Spontaneous breathing, transpulmonary pressure and mathematical trickery

Basing Respiratory Management of COVID-19 on Physiological Principles

A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine

Reliability of methods to estimate the fraction of inspired oxygen in patients with acute respiratory failure breathing through non-rebreather reservoir bag oxygen mask

High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis

Prediction of outcome of nasal high flow use during COVID-19-related acute hypoxemic respiratory failure

Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient

High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion

High-flow nasal therapy in adults with severe acute respiratory infection: A cohort study in patients with 2009 influenza A/H1N1v

The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing

Acute Physiology and Chronic Health Evaluation II Score as a Predictor of Hospital Mortality in Patients of Coronavirus Disease

High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study

Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave?

We thank all the staff who participated in the management of patients and data collection. The authors are grateful to Nikki Sabourin-Gibbs, Rouen University Hospital, for her precious help in editing the manuscript.